12 results about "Beta-cell Function" patented technology

The invention discloses a composite combined preparation for synergistically treating and conditioning diabetes, relates to the technical field of foods, health foods or dietary supplements for adjuvant therapy and health care of diabetes, and in particular relates to a composite combined preparation for synergistically treating and conditioning diabetes. The preparation comprises albumin peptide, saussurea involucrata culture, vitamin B1, vitamin B2, wheat oligopeptide, corn oligopeptide, collagen peptide, mulberry leaf extract, rhizoma polygonati extract, sea-buckthorn extract, isomaltitol, maltodextrin, ginseng extract and bitter gourd extract. Through the synergistic effect of all the components, comprehensive auxiliary conditioning on diabetes is realized from multiple targets of maintaining colloid osmotic pressure and nutrition, regulating glycolipid metabolism in multiple ways, protecting pancreatic beta cell functions, enhancing insulin sensitivity, preventing nerve and blood vessel complications, meeting special diet requirements and the like. The composition can be prepared into food, health-care food or dietary supplement and other dosage forms.

The invention relates to the technical field of functional reconstruction of functional beta cells of diabetic patients, in particular to a design method and device for functional reconstruction of beta cells based on single-cell multi-omics and a development potential energy field, and is suitable for accurate design and verification of a functional beta cell regeneration treatment scheme of the diabetic patients. According to the method and the device disclosed by the invention, efficient design and verification of a personalized beta cell function reconstruction scheme are realized by integrating single-cell multi-omics data, an embryonic development mechanism and an optimal control theory.

The invention belongs to the field of new application of medicines, and particularly relates to application of triptolide in preparation of medicines for treating diabetic vascular obstruction complications. Diabetes vascular obstruction is a common serious complication of diabetes and can cause various tissue injuries such as cardiovascular diseases, nephropathy and retinopathy. Experiments prove that the triptolide can remarkably improve the problems of blood vessel blockage, blood flow slowing, abnormal neovascularization and the like caused in a high-glucose environment, and meanwhile, the expression of blood glucose related indexes (such as Glucose and HbA1c) and inflammatory factors (such as TNF-alpha and IL-1beta) is reduced. In addition, triptolide can also protect pancreas from high glucose damage and improve functions of pancreatic beta cells. According to the invention, the clinical application range of the triptolide is expanded, and a new candidate substance is provided for drug treatment of diabetic vascular complications.

This invention discloses a method for constructing a type 2 diabetes mouse model combining artificial intelligence prediction and multi-target knockout. The method involves acquiring and standardizing multi-omics data and baseline phenotypic data of mice to form a standardized modeling dataset; constructing an interaction map covering pancreatic β-cell function based on this data; selecting target target combinations and target phenotypic prediction results; generating construction instructions and submitting them to a controlled facility for multi-gene knockout modification to obtain modified mice and modification receipts; obtaining measured phenotypic data of the modified mice based on the modification receipts; comparing this data with the target phenotypic prediction results to generate phenotypic deviation metrics and phenotypic determination results; and registering the target target combinations, prediction results, measured phenotypic data, and modification receipts when the phenotypic determination results are satisfactory to form a type 2 diabetes composite mouse model. This invention achieves closed-loop optimization of AI-driven multi-target genetic modification, improving the efficiency and accuracy of constructing animal models of complex metabolic diseases.

This invention belongs to the field of biomedical technology and discloses the application of NP in the preparation of a glycemic regulator for aging type 2 diabetes. The NP is a nanoscale complex formed by hydrogen bonding of turtle egg peptide with a molecular weight less than 3 kDa and naringenin at a mass ratio of 100:1. The formulation promotes liver glycogen synthesis and repairs pancreatic tissue structure and pancreatic β-cell function by activating the hepatic IRS1 / PI3K / AKT / GSK-3β signaling pathway and upregulating GLUT2 protein expression. The NP provided by this invention can significantly reduce fasting blood glucose levels in aging type 2 diabetic mice, improve oral glucose tolerance, and reduce the area under the blood glucose curve. Simultaneously, by restoring insulin signal transduction, it significantly reduces the insulin resistance index and improves the insulin sensitivity index, with an improvement level approaching that of the classic hypoglycemic drug metformin.

The invention relates to the field of biological medicines, in particular to application of a hepatocyte nuclear factor 1 alpha (HNF1 alpha) in promoting beta cell regeneration and preventing and treating diabetes. Specifically, by regulating and controlling the expression of an HNF1alpha coding gene and the activity of HNF1alpha, pancreas islet alpha cells can be promoted to be transdifferentiated into beta cells to achieve beta cell regeneration, the functions of pancreas islet beta cells are reserved, the occurrence of diabetes mellitus is delayed, and a new medical approach is provided for prevention and treatment of diabetes mellitus.

The invention discloses an application of a jerusalem artichoke tuber alcohol extract in preparation of a medicine for treating type 2 diabetes mellitus, and belongs to the technical field of medicines, the chemical components of the jerusalem artichoke tuber alcohol extract are mainly flavonoid substances, and the jerusalem artichoke tuber alcohol extract can remarkably recover the weight of a mouse with the type 2 diabetes mellitus and improve glucose metabolism indexes such as fasting blood-glucose and oral glucose tolerance; meanwhile, insulin sensitivity is stimulated to secrete insulin, and the functions of pancreatic beta cells are recovered; in addition, the concentration of biochemical indexes such as total cholesterol and triglyceride in the liver is reduced, lipid metabolism of the liver is improved, and a new direction is provided for research and development of natural plant source hypoglycemic products.

The invention discloses a fusion protein for regulating and controlling functions of pancreatic beta cells based on an optogenetics technology and application of the fusion protein, and relates to the technical field of biology. The fusion protein Opto LOVTRAP disclosed by the invention has very high temporal-spatial resolution, and rapid and accurate control on a single cell can be realized by adjusting blue light; opto LOVTRAP has reversibility, can effectively inhibit a pancreatic beta cell Ca < 2 + > channel under a dark condition, and can quickly stop playing a role after being stimulated by blue light, so that the purpose of reversibly and accurately regulating insulin secretion is achieved. Opto LOVTRAP is targeted to regulate the concentration of Ca < 2 + > in cells, and is a final triggering factor for release of pancreas islet vesicles, so that the opto LOVTRAP is not influenced by the KATP function, and the purpose of breaking through the bottleneck of a traditional clinical treatment mode is achieved.

The application provides application of ceramide hydrolase ACER2 in preparation of a medicine for improving beta cell function, preventing and / or treating diabetes. The application proves, for the first time, through a pancreatic islet beta cell damage regeneration model and a diabetes mouse model, that ACER2 is indispensable for regulating ceramide level, improving beta cell function and diabetes pathological phenotype by specifically knocking out a metabolic enzyme ACER2 of vascular endothelial cells; and constructs extracellular vesicles overexpressing ACER2, and proves that the extracellular vesicles overexpressing ACER2 have certain application prospect in improvement of pancreatic islet beta cell function and treatment of diabetes.

The application relates to the technical field of stem cell engineering and regenerative medicine, and specifically discloses a stem cell treatment method for treating type 2 diabetes. The method comprises the following steps: S1, extracting placenta-derived mesenchymal stem cells; S2, performing multi-gene modification on the mesenchymal stem cells to obtain gene-modified mesenchymal stem cells; S3, pretreating the gene-modified mesenchymal stem cells with a culture medium; S4, extracting microvesicles from the mesenchymal stem cells; S5, mixing the microvesicles, baicalin, L-arginine and vitamin D in a buffer to form a composite preparation; S6, introducing the composite preparation into a patient's body through abdominal cavity intervention; and S7, performing synergistic treatment by combining oral administration of an SGLT2 inhibitor after infusion, and regularly monitoring islet function indexes. The stem cell treatment method can be used for treating type 2 diabetes, and has the advantages of being targeted to improve the islet microenvironment, promoting the recovery of beta cell function and being durable in action.

The present application relates to the technical field of biological medicine and gene therapy, and particularly relates to a nucleic acid delivery system targeting pancreatic beta cells and application thereof. The nucleic acid delivery system comprises a nanocomplex formed by a cationic polymer modified with a targeting ligand and siRNA; the targeting ligand is a GLP-1 receptor targeting peptide; the cationic polymer is a PEI-PFA polymer; and the siRNA is siRNA targeting DYRK1A. The present application provides a novel pancreatic beta cell targeting delivery platform for gene therapy of type 2 diabetes. The platform realizes beta cell function regeneration by precisely regulating DYRK1A gene expression, and has targeting, safety and high efficiency, thereby providing a new strategy with broad clinical application prospect for diabetes treatment.

The invention discloses a tanlotide series composition with functions of improving pancreatic beta cell functions, regulating blood fat, repairing liver and kidney injury, resisting inflammation and resisting oxidation and application thereof, and belongs to the technical field of medicines. The composition is prepared from radix trichosanthis, radix puerariae, radix ophiopogonis, radix codonopsis, poria cocos, fructus mume, radix astragali seu hedysari preparata, radix glycyrrhizae, fructus schisandrae chinensis, radix rehmanniae, folium eriobotryae powder, epigallocatechin gallate, instant bean flour, corn oligopeptide powder, wheat oligopeptide powder and soybean peptide powder, and meanwhile, the composition further comprises synergistic components. The synergistic component is one or more of a ginseng extract, PQQ, a turmeric extract and black pepper powder, and the composition has the effect of improving the functions of pancreatic beta cells and can effectively reduce the insulin resistance index. The traditional Chinese medicine composition also has a remarkable effect of regulating blood fat, and meanwhile, can repair liver and kidney injuries caused by complications such as hyperglycemia and hyperlipidemia. In addition, it is found that the composition has good anti-inflammatory and anti-oxidation effects, inflammation caused by in-vivo tissue lesions can be effectively resisted, meanwhile, the content of glutathione peroxidase and superoxide dismutase in the body is increased, and tissue cell recovery is accelerated through the combined action of the glutathione peroxidase and the superoxide dismutase.